NCT04680091Unknown1 期
A Single-Center, Single-Arm, Open-Label, Fixed-Sequence Phase I Drug-Drug Interaction Clinical Study of the Effect of Efavirenz on Pharmacokinetics of Maleate Pyrotinib in Chinese Healthy Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Summary of Pharmacokinetic parameters Maximum Plasma Concentration (Cmax) for pyrotinib.
研究概览
简要总结
This drug-drug interaction (DDI) study had been designed to investigate the effect of a moderate CYP 3A inducer efavirenz on the pharmacokinetics of maleate pyrotinib in Chinese healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
- •Ability to complete the study as required by the protocol;
- •Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
- •Body weight ≥ 50 kg for male and female, and body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);
- •In females, documented surgical sterilization, postmenopausal status for at least 1 year (follicle stimulating hormone [FSH] > 40 mIU/mL serum at Screening), or agreement to use an approved form of contraception
- •In males, agreement to avoid sperm donation for 6 months days after the dose of pyrotinib
- •Liver function test results must be below the upper limit of normal.
- •Participants must agree to refrain from donation of whole blood and other blood products from 90 days prior to Screening,
排除标准
- •Loss of more than 400 mL blood during the 3 months before the trial (eg, as a blood donor)
- •Allergic constitution;
- •History of drug use, or drug abuse screening positive;
- •Alcoholic or often drinkers;
- •A smoker with 5 cigarettes per day for more than 90 days;
- •Positive serology for hepatitis B surface antigen (HBsAg) and HCV (healthy participants), anti-treponema pallidum virus (TP), or antihuman immunodeficiency virus (HIV) Type 1 and Type 2 (all subjects)
- •Use of any drugs or substances known to be inhibitors or inducers of CYP3A4/5 within 90 days from the first dose or 5 half-lives, if known, of the drugs or substances, whichever is greater, prior to pyrotinib administration and during the study.
- •A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
- •Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases.
研究组 & 干预措施
Efavirenz 600 mg + Pyrotinib 400 mg
Experimental
干预措施: Efavirenz (Drug)
Efavirenz 600 mg + Pyrotinib 400 mg
Experimental
干预措施: Pyrotinib Maleate (Drug)
Pyrotinib 400 mg
Active Comparator
干预措施: Pyrotinib Maleate (Drug)
结局指标
主要结局
Summary of Pharmacokinetic parameters Maximum Plasma Concentration (Cmax) for pyrotinib.
时间窗: predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve from 0 to any time before the last quantifiable concentration (AUC0-t) for pyrotinib.
时间窗: predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve from 0 to infinite time (AUCinf) for pyrotinib.
时间窗: predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20
次要结局
- The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0): Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination, vital signs, etc.(Baseline up to 14 days post last dose, up to approximately 2 month)
- Pharmacokinetics parameters (Tmax) of pyrotinib;(predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20)
- Pharmacokinetics parameters (T1/2) of pyrotinib;(predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20)
- Pharmacokinetics parameters (CL) of pyrotinib;(predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20)
- Pharmacokinetics parameters (Vd) of pyrotinib;(predose, 1, 2, 3, 4, 4.5, 5, 5.5, 7, 9, 12, 24, 48, 72, 96 h for Day1 and predose, 0.5, 1, 1.75, 2.5, 3.25, 4, 4.75, 5.5, 6.5, 8, 12, 24, 48, 72 h for Day20)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsHealthy SubjectsDrug-drug InteractionPharmacokineticsQuizartinibNCT04459598Daiichi Sankyo Co., Ltd.32
已完成
1 期
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459NCT04649723Jiangsu HengRui Medicine Co., Ltd.20
已完成
1 期
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001Fungal InfectionNCT04166669Basilea Pharmaceutica36
已完成
1 期
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelElevated Lipoprotein(a)Cardiovascular DiseasesNCT03392051Akcea Therapeutics18
已完成
1 期
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy SubjectsChronic Hepatitis BNCT03662568Sunshine Lake Pharma Co., Ltd.56